Clinical Trials, Study Results and Plain Language Results Summaries - Clinical Trials - Research & Development

The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as ClinicalTrials.gov, EU-Clinical Trial Register and JapicCTI/jRCT, are provided for informational purposes only, and are not intended to promote any product. Clinical study reports provide results known at the time of the study completion and analysis. Therefore, the results provided may not provide either a complete or current review of the safety and efficacy of the pharmaceutical product studied.
Health care providers and patients should refer to the current product labeling for detailed information on approved indications in their country or region.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medication is the correct or best treatment option for a particular patient. If you have questions, please consult with a health care professional.

Search by Disease Name, Project Code, Generic Name or Study Code

Find clinical trial information available in Japanese language

A

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Axicabtagene Ciloleucel	YESCARTA®	Diffuse Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Transformed Follicular Lymphoma; High Grade B-cell Lymphoma	KTEC19-A-J901	jRCT2013210008
Axicabtagene Ciloleucel	YESCARTA®	Large B Cell Lymphoma	KTEC19-A-J201	JapicCTI-183914
Azelnidipine	CALBLOCK®	Hypertension	CB502-021	JapicCTI-050028
AC430	Discontinued	Healthy Subjects	AC430-001	NCT01287858
AC480IV	Discontinued	Advanced Solid Cancer	AC480IV-001	NCT01245543
ASB17061	Discontinued	Atopic Dermatitis	ASBI 704	NCT01756898	Tabulated Results (CT.gov)

B

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Baclofen	GABALON®	Spastic Paralysis	DL404-02P	JapicCTI-050031	Summary Results (JapicCTI)
Baclofen	GABALON®	Spastic Paralysis	DL404-01	JapicCTI-050061

C

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-203	jRCT2031220399
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-202	jRCT2031220400
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-103	jRCT2031220264
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-146	jRCT2071210106
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-116	jRCT2071210086
COVID-19 mRNA Vaccine (DS-5670)		Prevention of Infectious Disease by SARS-CoV-2	DS5670-A-J101	NCT04821674 jRCT2071200110
Carperitide	HANP®	Congestive Heart Failure; Myocardiopathies	03-0-162	NCT00259038
Carvedilol	ARTIST®	Atrial Fibrillation	DQ2466-A-J301	JapicCTI-132201	Journal Publication
Colesevelam HCl	WELCHOL®	Pediatric Type 2 Diabetes Mellitus	WEL-A-U307	NCT01258075	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-A-U306	NCT00789750	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-305	NCT00789737	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia	WEL-407	NCT00755352
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia	WEL-406	NCT00754507
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia; Hyperlipidemia, Familial Combined	WEL-403	NCT00754039
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia	WEL-405	NCT00753779
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus; Hyper-cholesterolemia; Pre-diabetes	WEL-411	NCT00570739	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-409	NCT00484419	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-202	NCT00361153
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia	WEL-408	NCT00185107
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-304	NCT00151762
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-302	NCT00151749
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-303	NCT00147758
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-201	NCT00147745	Tabulated Results (CT.gov)
Colesevelam HCl	WELCHOL®	Type 2 Diabetes Mellitus	WEL-301	NCT00147719
Colesevelam HCl	WELCHOL®	Hyper-cholesterolemia	WEL-410	NCT00145574 2005-003511-75	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Cevimeline Hydrochloride	EVOXAC®	Xerostomia	CDR0000068698	NCT00017511
CS-0777	Discontinued	Multiple Sclerosis	CS0777-A-U102	NCT00616733
CS-1036	Discontinued	Diabetes	CS1036-A-A201	JapicCTI-101069
CS-1036	Discontinued	Diabetes	CS1036-A-J202	JapicCTI-101121
CS-4771	Discontinued	Healthy Subjects	CS4771-A-J105	JapicCTI-121939
CS-801	Discontinued	Overactive Bladder	150-010	JapicCTI-050025
CS-801	Discontinued	Overactive Bladder	150-006	JapicCTI-050026
CS-8080	Discontinued	Healthy Subjects	CS8080-A-U102	NCT00796575
CS-8080	Discontinued	Healthy Subjects	CS8080-A-U101	NCT00613431
CS-917	Discontinued	Type 2 Diabetes Mellitus	CS0917-A-U205	NCT00290940
CS-917	Discontinued	Type 2 Diabetes Mellitus	CS0917-A-E-107	2004-003195-11	Summary Results (EU-CTIS)

D

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Datopotamab Deruxtecan (DS-1062)		Triple Negative Breast Cancer	TROPION-Breast03 D926XC00001	jRCT2061220087
Datopotamab Deruxtecan (DS-1062)		Non-small Cell Lung Cancer	TROPION-Lung07 DS1062-A-U303	NCT05555732 2022-500802-16 jRCT2061220066
Datopotamab Deruxtecan (DS-1062)		Triple Negative Breast Cancer	TROPION-Breast02 D926PC00001	jRCT2061220029
Datopotamab Deruxtecan (DS-1062)		Non-small Cell Lung Cancer	TROPION-Lung08 DS1062-A-U304	NCT05215340 2021-002555-10 jRCT2061210074
Datopotamab Deruxtecan (DS-1062)		Breast Cancer	TROPION-Breast01 D9268C00001	jRCT2031210440
Datopotamab Deruxtecan (DS-1062)		Non-small Cell Lung Cancer	TROPION-Lung01 DS1062-A-U301	NCT04656652 2020-004643-80 jRCT2071200104
Datopotamab Deruxtecan (DS-1062)		Non-small Cell Lung Cancer	TROPION-Lung02 DS1062-A-U102	NCT04526691 jRCT2031200193
Datopotamab Deruxtecan (DS-1062)		Non-small Cell Lung Cancer	TROPION-Lung05 DS1062-A-U202	NCT04484142 2020-002774-27 jRCT2041200097
Datopotamab Deruxtecan (DS-1062)		Solid Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Cancer	DS1062-A-J101	NCT03401385 JapicCTI-173812
DS-1001		Glioma	DS1001-A-J201	NCT04458272 JapicCTI-205339
DS-1001		Glioma	DS1001-A-J101	NCT03030066 JapicCTI-163479
DS-1055		Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Other Types of Solid Cancer	DS1055-A-J101	NCT04419532 JapicCTI-205292
DS-1211		Pseudoxanthoma Elasticum	DS1211-A-U201	NCT05569252
DS-1211		Pseudoxanthoma Elasticum	DS1211-A-U104	NCT05025722
DS-2325		Netherton Syndrome	DS2325-106	NCT05583669
DS-2325		Netherton Syndrome	DS2325-104	NCT05388903
DS-6000		Renal Cancer; Ovarian Cancer	DS6000-A-U101	NCT04707248 jRCT2031220075
DS-6016		Healthy Subjects	DS6016-A-J101	NCT04818398 jRCT2051200155
DS-7011		Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus	DS7011-107	NCT05638802
DS-7011		Healthy Subjects	DS7011-A-U101	NCT05203692
DS-9606		Ovarian Cancer; Germ Cell Tumor; Advanced Solid Tumors	DS9606-137	NCT05394675 2022-000120-38
Denosumab	PRALIA®	Rheumatoid Arthritis	AMG162-D-J301	NCT01973569 JapicCTI-132277	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Denosumab	RANMARK®	Multiple Myeloma	20090482	JapicCTI-121876	Summary Results (JapicCTI)
Denosumab	RANMARK®	Bone Metastases	20110113	JapicCTI-121868	Summary Results (JapicCTI)
Denosumab	RANMARK®	Giant Cell Tumor of Bone	AMG162-B-J201	JapicCTI-111665	Journal Publication
Denosumab	PRALIA®	Rheumatoid Arthritis	AMG162-D-J201	JapicCTI-101263	Summary Results (JapicCTI)
Denosumab	RANMARK®	Breast Cancer	20060359	JapicCTI-101163	Summary Results (JapicCTI)
Denosumab	RANMARK®	Breast Cancer	20050136	JapicCTI-090906	Journal Publication
Denosumab	PRALIA®	Osteoporosis	AMG162-A-J301	NCT00680953 JapicCTI-090797	Tabulated Results (CT.gov) Journal Publication Journal Publication
Diphtheria Pertussis Tetanus Combined Vaccine	Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine	Prevention of Diphtheria; Tetanus; Pertussis	VN0103-A-J301	JapicCTI-142535
DS-1205	Out-licensed	Non-small Cell Lung Cancer	DS1205-A-J102	NCT03599518 JapicCTI-184026	Tabulated Results (CT.gov)
DS-1205	Out-licensed	Non-small Cell Lung Cancer	DS1205-A-U101	NCT03255083 2017-000542-21	Tabulated Results (CT.gov)
DS-6051	Out-licensed	Advanced Solid Malignant Tumors	DS6051-A-J102	NCT02675491 JapicCTI-153111
DJ-927	Discontinued	Colorectal Cancer	CDR0000356034	NCT00080834
DJ-927	Discontinued	Solid Cancer	CDR0000346368	NCT00077077
DJ-927	Discontinued	Non-small Cell Lung Cancer	927E-PRT007	2004-000696-34	Summary Results (EU-CTIS)
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-U103	NCT02586233 2015-001824-43	Tabulated Results (CT.gov)
DS-1040	Discontinued	Acute Submassive Pulmonary Embolism	DS1040-B-U107	NCT02923115 2015-005211-32	Tabulated Results (CT.gov)
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-J110	NCT03198715 JapicCTI-173612	Tabulated Results (CT.gov) Summary Results (JapicCTI)
DS-1040	Discontinued	Healthy Subjects	DS1040-A-E108	NCT02647307 2015-003470-32
DS-1040	Discontinued	Healthy Subjects	DS1040-A-E106	NCT02560688 2015-003018-26
DS-1040	Discontinued	Acute Ischemic Stroke	DS1040-A-E102	NCT02071004
DS-1093	Discontinued	Healthy Subjects	DS1093-A-E102	NCT02142400 2014-000552-28
DS-1093	Discontinued	Kidney Disease	DS1093-A-E103	NCT02299661 2014-002331-33
DS-1123	Discontinued	Advanced Solid Tumours	DS1123-A-J101	NCT02690337 JapicCTI-153085
DS-1150	Discontinued	Type 2 Diabetes Mellitus	DS1150-A-U101	NCT02004678
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E106	NCT02564861 2015-002885-22
DS-1971	Discontinued	Type 2 Diabetes Mellitus; Neuropathic Pain	DS1971-A-U202	NCT02673866
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E105	NCT02473627 2015-000330-30
DS-1971	Discontinued	Pain	DS1971-A-J201	JapicCTI-163193
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E104	NCT02266940 2014-003662-24
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E103	NCT02261376 2014-003019-13
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E102	NCT02190058 2014-001800-23
DS-1971	Discontinued	Healthy Subjects	DS1971-A-E101	NCT02107885 2014-000240-15
DS-2248	Discontinued	Solid Cancer	DS2248-A-U101	NCT01288430 2011-002666-21	Tabulated Results (CT.gov)
DS-2330	Discontinued	Chronic Hemodialysis	DS2330-A-U103	NCT03305471
DS-2741	Discontinued	Atopic Dermatitis; Healthy Subjects	DS2741-A-J101	NCT04211415 JapicCTI-195071
DS-3078	Discontinued	Solid Cancer; Lymphomas	DS3078-A-U101	NCT01588678 2011-005988-24
DS-5573	Discontinued	Advanced Solid Malignant Tumors	DS5573-A-J101	NCT02192567 JapicCTI-142586
DS-6157	Discontinued	Gastrointestinal Stromal Tumor	DS6157-A-U101	NCT04276415 JapicCTI-205184
DS-7080	Discontinued	Macular Degeneration	DS7080-A-U101	NCT02530918
DS-7250	Discontinued	Diabetes	DS7250-A-J201	JapicCTI-121963
DS-7309	Discontinued	Type 2 Diabetes Mellitus	DS7309-A-U102	NCT01956305
DS-7309	Discontinued	Type 2 Diabetes Mellitus	DS7309-A-U101	NCT01862939
DS-7423	Discontinued	Solid Cancer; Colorectal Cancer; Endometrial Cancer	DS7423-A-U101	NCT01364844
DS-7423	Discontinued	Solid Cancer	DS7423-A-J102	JapicCTI-121766
DS-8273	Discontinued	Advanced Colorectal Cancer	DS8273-A-U103	NCT02991196
DS-8273	Discontinued	Advanced Solid Cancer; Lymphomas	DS8273-A-U101	NCT02076451
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J204	NCT02685345 JapicCTI-163136
DS-8500	Discontinued	Hepatic or Renal Impairment	DS8500-A-J107	JapicCTI-163135
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J205	NCT02669732 JapicCTI-163126
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J203	NCT02628392 JapicCTI-153068
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-U202	NCT02647320	Tabulated Results (CT.gov)
DS-8500	Discontinued	Type 2 Diabetes Mellitus	DS8500-A-J201	NCT02222350 JapicCTI-142597
DS-8500	Discontinued	Healthy Subjects	DS8500-A-J103	JapicCTI-173550
DS-8500	Discontinued	Healthy Subjects	DS8500-A-J108	JapicCTI-163233
DS-8500	Discontinued	Healthy Subjects	DS8500-A-J110	JapicCTI-163299
DS-8500	Discontinued	Healthy Subjects	DS8500-A-U105	NCT03699774
DS-8500	Discontinued	Healthy Subjects	DS8500-A-U112	NCT02790684
DS-8500	Discontinued	Healthy Subjects	DS8500-A-U109	NCT02790671
DS-8500	Discontinued	Healthy Subjects	DS8500-A-J106	JapicCTI-152878
DS-8500	Discontinued	Healthy Subjects	DS8500-A-J104	JapicCTI-142673
DS-8895	Discontinued	Advanced Solid Cancer	DS8895-A-J101	NCT02004717 JapicCTI-132306
DS-9231 (TS23)	Discontinued	Acute Pulmonary Embolism	DS9231-A-U201	2017-000552-25

E

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	EDX/18/0414(2)	NCT05262322
Edoxaban	SAVAYSA®; LIXIANA®	Non-valvular Atrial Fibrillation	DSCN-ETNA AF-RWS-001	NCT04747496
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	ETAF-TR-01	NCT04594915
Edoxaban	SAVAYSA®; LIXIANA®	Non-valvular Atrial Fibrillation	DS-EDO-01-20-DE	NCT04519944
Edoxaban	SAVAYSA®; LIXIANA®	Cardiac Disease	DU176b-C-U313	NCT03395639 2017-000475-90	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-C-A4012	NCT03247582
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-C-A4011	NCT03247569
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-D-A4010	NCT02952599
Edoxaban	SAVAYSA®; LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-C-A4008	NCT02951039
Edoxaban	SAVAYSA®; LIXIANA®	Non-Valvular Atrial Fibrillation	DU176B-C-U4001	NCT02943785 2016-003930-26	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation; Venous Thromboembolism	DSE-EDO-02-15-EU	NCT02950168
Edoxaban	SAVAYSA®; LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-C-E314	NCT02964949 2016-001795-30	Tabulated Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DSE-EDO-05-14-EU	NCT02943993	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Non Valvular Atrial Fibrillation	DSE-EDO-04-14-EU	NCT02944019
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DSE-EDO-01-16-EU	NCT02942576 2016-003069-25	Tabulated Results (CT.gov) (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Non-Valvular Atrial Fibrillation	DSE-EDO-01-15-EU	NCT02866175 2016-002683-14	Tabulated Results (CT.gov) (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Non-valvular Atrial Fibrillation	DU176b-C-J316	NCT02801669 JapicCTI-163266	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-D-U312	NCT02798471 2016-000991-49	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Edoxaban	SAVAYSA®; LIXIANA®	Deep Vein Thrombosis; Venous Thromboembolism	DU176b-A-U157	NCT02303431 2015-005732-18	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Cancer	DU176b-D-U311	NCT02073682 2014-004708-30	Tabulated Results (CT.gov) (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-F-E308	NCT02072434 2013-003148-21	Tabulated Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Peripheral Arterial Disease	DU176b-E-U210	NCT01802775 2012-003009-88	Tabulated Results (CT.gov) (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Non-valvular Atrial Fibrillation	DU176b-C-J307	JapicCTI-111716	Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-B-J307	NCT01857622	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-B-J306	NCT01857583	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Non-Valvular Atrial Fibrillation	DU176b-D-U211	NCT01662908	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism; Thromboembolism; Thrombosis; Deep Vein Thrombosis; Arthroplasty; Hip Replacement	DU176b-B-J209	NCT01203098 JapicCTI-090827	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Deep-Vein Blood Clots; Lung Blood Clots	DU176b-D-U305	NCT00986154 2009-014290-40 JapicCTI-101043	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-B-J304	NCT01181167 JapicCTI-090771	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-B-J303	NCT01181141 JapicCTI-090798	Tabulated Results (CT.gov) Journal Publication
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-B-J302	NCT01181102 JapicCTI-090727	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-C-U301	NCT00781391 2008-004522-16 JapicCTI-090775	Tabulated Results (CT.gov) Summary Results (EU-CTIS) Journal Publication
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-C-J225	NCT00829933 JapicCTI-070391	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-C-J226	NCT00806624	Tabulated Results (CT.gov)
Edoxaban	SAVAYSA®; LIXIANA®	Venous Thromboembolism	DU176b-04	NCT01203072 JapicCTI-060283	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Edoxaban	SAVAYSA®; LIXIANA®	Atrial Fibrillation	DU176b-PRT018	NCT00504556 2007-001271-11	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Thrombosis; Hip Replacement	DU176b-PRT011	NCT00398216 2006-000758-29	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Arthroplasty, Hip Replacement; Thrombosis	DU176b-PRT007	NCT00107900 2004-004415-29	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Edoxaban	SAVAYSA®; LIXIANA®	Healthy Subjects	DU176b-A-U158	NCT02047565
Esaxerenone	MINNEBRO®	Type 2 Diabetes	CS3150-B-J309	JapicCTI-173696	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Type 2 Diabetes	CS3150-B-J308	JapicCTI-173695	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Type 2 Diabetes Mellitus	CS3150-B-J204	NCT02345057 JapicCTI-152774
Esaxerenone	MINNEBRO®	Diabetes	CS3150-B-J202	JapicCTI-122018
Esaxerenone	MINNEBRO®	Primary Aldosteronism	CS3150-A-J307	NCT02885662 JapicCTI-163349	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J303	NCT02848170 JapicCTI-163324	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Hypertension With Type 2 Diabetes and Albuminuria	CS3150-A-J306	NCT02807974 JapicCTI-163293	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Severe Hypertension	CS3150-A-J304	NCT02808026 JapicCTI-163287	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Moderate Renal Impairment; Hypertension	CS3150-A-J305	NCT02807987 JapicCTI-163288	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J301	NCT02890173 JapicCTI-163348	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Essential Hypertension	CS3150-A-J302	NCT02722265 JapicCTI-163176	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Hypertension; Moderate Renal Impairment	CS3150-A-J206	NCT02448628 JapicCTI-152883	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Hypertension	CS3150-A-J203	NCT02345044 JapicCTI-152772	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Hypertension	CS3150-A-J201	JapicCTI-121921	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-C-J101	JapicCTI-194837	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J112	JapicCTI-163452	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J111	JapicCTI-163443	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J110	JapicCTI-163379	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Hepatic Impairment	CS3150-A-J109	JapicCTI-163339	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J108	JapicCTI-163286	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J107	JapicCTI-152832	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-U106	NCT04019652
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J102	JapicCTI-163476	Summary Results (JapicCTI)
Esaxerenone	MINNEBRO®	Healthy Subjects	CS3150-A-J101	JapicCTI-163473	Summary Results (JapicCTI)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-J111	JapicCTI-101230
Efatutazone	Discontinued	Non-Smal Cell Lung Cancer	CS7017-A-A110	NCT01199068	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Non-Smal Cell Lung Cancer	CS7017-A-A108	NCT01199055	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Solid Cancer	CS7017-A-J107	JapicCTI-090968
Efatutazone	Discontinued	Lung Cancer	CS7017-A-U204	NCT01101334 2009-016083-36	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-E201	NCT00986440 2008-005848-16	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Efatutazone	Discontinued	Colorectal Cancer	CS7017-A-U203	NCT00967616	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Cancer	CS7017-A-U102E	NCT00881569	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Lung Cancer	CS7017-A-U202	NCT00806286 2009-013428-22	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Anaplastic Thyroid Cancer	CS7017-A-U103	NCT00603941	Tabulated Results (CT.gov)
Efatutazone	Discontinued	Neoplasm	CS7017-A-U102	NCT00408434	Tabulated Results (CT.gov)
Enbrel BS	Discontinued	Rheumatoid Arthritis	CHS-0214-02	JapicCTI-142621
Enbrel BS	Discontinued	Rheumatoid Arthritis	CHS-0214-05	JapicCTI-152927
Exatecan Mesylate	Discontinued	Sarcoma	CDR0000271889	NCT00055952
Exatecan Mesylate	Discontinued	Sarcoma	CDR0000271888	NCT00055939
Exatecan Mesylate	Discontinued	Pancreatic Cancer	CDR0000068880	NCT00023972
Exatecan Mesylate	Discontinued	Esophageal Cancer; Gastric Cancer	CDR0000068663	NCT00017212
Exatecan Mesylate	Discontinued	Biliary Cancer	CDR0000067736	NCT00005938
Exatecan Mesylate	Discontinued	Cervical Cancer	CDR0000067525	NCT00004866
Exatecan Mesylate	Discontinued	Brain and Central Nervous System Cancer; Lymphoma; Unspecified Childhood Solid Cancer	CDR0000067330	NCT00004212
Exatecan Mesylate	Discontinued	Liver Cancer	CDR0000067329	NCT00004108
Exatecan Mesylate	Discontinued	Ovarian, Fallopian Tube, or Peritoneal Cancer	CDR0000067258	NCT00004060
Exatecan Mesylate	Discontinued	Hematologic Cancer	CDR0000067149	NCT00004047
Exatecan Mesylate	Discontinued	Breast Cancer	CDR0000067148	NCT00004046
Exatecan Mesylate	Discontinued	Prostate Cancer	CDR0000067146	NCT00004045
Exatecan Mesylate	Discontinued	Pancreatic cancer	CDR0000067147	NCT00003951

G

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Ghrelin	Discontinued	Anorexia	SUN11031 (NA3801)	JapicCTI-090723
Ghrelin	Discontinued	Chronic Obstructive Pulmonary Disease	ASBI 307	NCT00698828 2007-007725-46	Tabulated Results (CT.gov) Summary Results (EU-CTIS)

H

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Hydromorphone	NARUVEIN®	Cancer Pain	DS7113-C-J306	JapicCTI-142736	Summary Results (JapicCTI)
Hydromorphone	NARUVEIN®	Cancer Pain	DS7113-C-J305	JapicCTI-142735	Summary Results (JapicCTI)
Hydromorphone	NARUSUS®	Cancer Pain	DS7113-B-J304	JapicCTI-142667	Summary Results (JapicCTI)
Hydromorphone	NARUSUS®	Cancer Pain	DS7113-B-J303	JapicCTI-142666	Summary Results (JapicCTI)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J302	JapicCTI-132288	Summary Results (JapicCTI)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J301	JapicCTI-132338	Summary Results (JapicCTI)
Hydromorphone	NARURAPID®	Cancer Pain	DS7113-A-J201	JapicCTI-132166	Summary Results (JapicCTI)
Hydromorphone	NARURAPID®; NARUSUS®	Healthy Subjects	DS7113-A-J102	JapicCTI-132167	Journal Publication

I

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Ifinatamab Deruxtecan (DS-7300)		Small-cell Lung Cancer	DS7300-127	NCT05280470 jRCT2041220019
Ifinatamab Deruxtecan (DS-7300)		Advanced Solid Cancer	DS7300-A-J101	NCT04145622 JapicCTI-194992
Influenza Vaccine Intranasal		Prevention of Influenza	VN0107-A-J301	JapicCTI-163400
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J303	JapicCTI-142554	Summary Results (JapicCTI)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J301	JapicCTI-121919	Summary Results (JapicCTI)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J302	JapicCTI-121968	Summary Results (JapicCTI)
Influenza Vaccine	Adsorbed Influenza Vaccine H5N1	Prevention of Influenza	KIBPCI-A-J201	JapicCTI-132190	Summary Results (JapicCTI)
Influenza Vaccine	Influenza HA Vaccine	Prevention of Influenza	VN0104-A-J201	JapicCTI-142587	Summary Results (JapicCTI)
Irinotecan	TOPOTECIN®	Small Cell Lung Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Ovarian Cancer; Gastric Cancer	Observational Study	JapicCTI-090946
Irinotecan	TOPOTECIN®	Colorectal Cancer	Observational Study	JapicCTI-090945
Irinotecan	TOPOTECIN®	Colorectal Cancer	TOP-003	NCT00284258 JapicCTI-060202
Irinotecan	TOPOTECIN®	Gastric Cancer	TOP-002	JapicCTI-050083	Summary Results (JapicCTI)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J301	JapicCTI-142493	Summary Results (JapicCTI)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J302	JapicCTI-142613	Summary Results (JapicCTI)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J303	JapicCTI-152991	Summary Results (JapicCTI)
Influenza Vaccine	Discontinued	Prevention of Influenza	VN100-A-J101	JapicCTI-132096	Summary Results (JapicCTI)
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J203	JapicCTI-142517
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J202	JapicCTI-142518
Ioforminol	Discontinued	Coronary Angiography	GE145-A-J201	JapicCTI-132391

L

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Laninamivir	INAVIR®	Influenza	CS8958-B-J311	JapicCTI-163398	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-B-J310	JapicCTI-163397	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J309	JapicCTI-142679	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J308	JapicCTI-142678	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza (Prophylaxis)	CS8958-A-J307	JapicCTI-111647	Journal Publication
Laninamivir	INAVIR®	Influenza	CS8958-A-J306	JapicCTI-090941	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J305	JapicCTI-090940	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-A202	JapicCTI-090826	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J304	JapicCTI-090814	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J303	JapicCTI-090813	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J302	JapicCTI-090812	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J301	NCT00803595	Tabulated Results (CT.gov)
Laninamivir	INAVIR®	Influenza	CS8958-A-J203	JapicCTI-090811	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Influenza	CS8958-A-J201	JapicCTI-090810	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Healthy Subjects	CS8958-B-J109	JapicCTI-152996	Summary Results (JapicCTI)
Laninamivir	INAVIR®	Healthy Subjects	CS8958-A-J108	JapicCTI-111441	Journal Publication
Levofloxacin	CRAVIT®	Infections	DR3355-B-J305	JapicCTI-121861	Summary Results (JapicCTI)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J304	JapicCTI-121898	Summary Results (JapicCTI)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J303	JapicCTI-121858	Summary Results (JapicCTI)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J302	JapicCTI-121844	Summary Results (JapicCTI)
Levofloxacin	CRAVIT®	Infections	DR3355-B-J301	JapicCTI-121819	Summary Results (JapicCTI)
Levofloxacin	CRAVIT®	Infections	DR3355-60	JapicCTI-070486	Summary Results (JapicCTI)

M

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Measles-Mumps-Rubella Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J301	JapicCTI-205118
Measles-Mumps-Rubella Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J302	JapicCTI-205117
Measles-Mumps-Rubella Vaccine		Prevention of Measles; Mumps; Rubella	VN0102-A-J303	JapicCTI-205114
Measles-Mumps-Rubella Vaccine		Prevention of Measles; Mumps; Rubella	JVC-001-P12-01	JapicCTI-153031	Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathic Pain	DS5565-A-A315	NCT04094662
Mirogabalin	TARLIGE®	Central Neuropathic Pain	DS5565-A-J314	NCT03901352 JapicCTI-194653	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-U307	NCT02496884 2014-003972-21	Tabulated Results (CT.gov) (EU-CTIS)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-E309	NCT02146430 2013-005161-40	Tabulated Results (CT.gov) (EU-CTIS)
Mirogabalin	TARLIGE®	Fibromyalgia	DS5565-A-E311	NCT02187159 2013-005163-10	Tabulated Results (CT.gov) (EU-CTIS)
Mirogabalin	TARLIGE®	Post-herpetic Neuralgia	DS5565-A-J304	NCT02318719 JapicCTI-142742	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Renal Impairment; Diabetic Peripheral Neuropathic Pain; Post-herpetic Neuralgia	DS5565-A-J313	NCT02607280 JapicCTI-153059	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Pain Associated With Fibromyalgia	DS5565-A-E310	NCT02187471 2013-005162-20	Tabulated Results (CT.gov) (EU-CTIS)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathic Pain	DS5565-A-J303	NCT02318706 JapicCTI-142741	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Pain Associated with Fibromyalgia	DS5565-A-E312	NCT02234583 2013-005164-26	Tabulated Results (CT.gov) (EU-CTIS)
Mirogabalin	TARLIGE®	Diabetic Peripheral Neuropathy	DS5565-A-U201	NCT01496365	Tabulated Results (CT.gov)
Mirogabalin	TARLIGE®	Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathic Pain	DS5565-A-J202	NCT01504412 JapicCTI-111713	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Renal Dysfunction	DS5565-A-J115	JapicCTI-132175	Summary Results (JapicCTI)
Mirogabalin	TARLIGE®	Healthy Subjects	DS5565-A-J316	JapicCTI-205156
Mirogabalin	TARLIGE®	Healthy Subjects	DS5565-A-A118	JapicCTI-173680	Summary Results (JapicCTI)
Memantine	MEMARY®	Alzheimer's Disease	SUNY7017-A-J301	JapicCTI-163209
Memantine	MEMARY®	Alzheimer's Disease	SUN Y7017 (IE3701)	JapicCTI-121743	Summary Results (JapicCTI)
Memantine	MEMARY®	Alzheimer's Disease	SUN Y7017 (MA3301)	JapicCTI-050079	Summary Results (JapicCTI)
Memantine	MEMARY®	Alzheimer's Disease	SUN Y7017 (IE3501)	JapicCTI-050078	Summary Results (JapicCTI)
Morphine Sulfate	MORPHABOND™️	Baseline Epidemiologic Assessment	MORPH-A-U403	NCT04033094
Milademetan	Out-licensed	Acute Myeloid Leukemia	DS3032-A-J104	NCT03671564 JapicCTI-184054	Summary Results (JapicCTI)
Milademetan	Out-licensed	Acute Myeloid Leukemia	DS3032-A-U105	NCT03552029	Tabulated Results (CT.gov)
Milademetan	Out-licensed	Hematological Malignancies	DS3032-A-U102	NCT02319369	Tabulated Results (CT.gov)
Milademetan	Out-licensed	Solid Cancer; Lymphomas	DS3032-A-J103	JapicCTI-142693	Summary Results (JapicCTI)
Milademetan	Out-licensed	Advanced Solid Cancer; Lymphomas	DS3032-A-U101	NCT01877382
Milademetan	Out-licensed	Healthy Subjects	DS3032-A-U115	NCT03647202
Milademetan	Out-licensed	Healthy Subjects	DS3032-A-U107	NCT03614455

N

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol
Nafamostat	Discontinued	Healthy Subjects	DS2319-A-J101	jRCT2051200153
Nimotuzumab	Discontinued	Lung Cancer	DE766-A-J303	JapicCTI-132084
Nimotuzumab	Discontinued	Esophageal Cancer	DE766-A-J102	JapicCTI-101319
Nimotuzumab	Discontinued	Non-small Cell Lung Cancer	DE766-A-J202	JapicCTI-090825
Nimotuzumab	Discontinued	Gastric Cancer	DE766-A-J201	JapicCTI-090849

O

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Ofloxacin	TARIVID®	Infections	8280A-PRT021	NCT00781521
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	CS0866-A-U301	NCT00151775 2015-003329-32	Tabulated Results (CT.gov) (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Metabolic Syndrome; Hypertension	DSE-866/47	NCT00676845 2007-003131-23	Summary Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension; Carotid Plaque	DSE-OLM-01-09	NCT01132768 2009-013342-92
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	866-447	NCT00185120
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Metabolic Syndrome; Hypertension	DSE-866/46	NCT00891267 2007-003130-41	Summary Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria	149-011/150-008 (ORIENT)	NCT00141453 JapicCTI-050027	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	CS0866-A-U452	NCT00949884	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Mild to moderate hypertension	SP-OLM-03-05	NCT00311155 2005-004659-36	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension; Renal Impairment	SE-866/43	NCT00151827
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	SS-866/01	NCT00856271
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	SS-866 CMB/01	NCT00872586
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Chronic Glomerulonephritis or Diabetic Nephropathy	CS0866-C-J201	NCT00914524
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Chronic Heart Failure; High Blood B-type (or Brain) Natriuretic Peptide Level	DSE-866-45	NCT00679484 2007-003060-22	Summary Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	CS0866-A-U102	NCT00151814 2015-003328-30	Tabulated Results (CT.gov) (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	866-451	NCT00430638	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Type 2 Diabetes Mellitus; Cardiovascular Disease; Kidney Disease	SE-866/44	NCT00185159 2004-000506-52	Summary Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	OLM004-071	NCT00858702	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	866-450	NCT00412932	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	TSP-866/01	NCT00857285	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	SPB-OM-0106	NCT00890591	Tabulated Results (CT.gov)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	866-432	NCT00772499
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Isolated Systolic Hypertension	SE-866/37	NCT00751829
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	SE-866/36	NCT00751751
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	SP-OLM-01-00	NCT00185172 2005-004659-36
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Atherosclerosis; Essential Hypertension	SE-866/27	NCT00185185
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Type 2 Diabetes Mellitus; Renal Disease	SE-866/29	NCT00362960
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Atherosclerosis	866-422 AIMS	NCT00382213
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Essential Hypertension	866-440	NCT00185094
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Healthy Subjects	866-448	NCT00185055
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Healthy Subjects	CS0866-A-U101	2015-003005-41	Tabulated Results (EU-CTIS)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	OMEGA study	JapicCTI-050002	Summary Results (JapicCTI)
Olmesartan Medoxomil	BENICAR®; OLMETEC®	Hypertension	PMS-OLM-200801	JapicCTI-101162	Summary Results (JapicCTI)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	DSE-SEV-02-09	NCT01101009
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	CS8663-404	NCT00791258	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Type 2 Diabetes Mellitus; Hypertension	CS-8663-403	NCT00654745	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	8663-402	NCT00527514	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	CS8663-A-U301	NCT00185133
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Essential Hypertension	CS8663-A-E303	NCT00220233 2005-000450-75	Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Essential Hypertension	CS8663-A-E302	NCT00220220 2005-000447-28	Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Essential Hypertension	DSE-SEV-02-09	2009-012966-30	Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Healthy Subjects	SS8663-03	JapicCTI-111580	Journal Publication
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	SS8663-02	JapicCTI-111581	Journal Publication
Olmesartan Medoxomil + Amlodipine	AZOR®; SEVIKAR®	Hypertension	SS8663-01	JapicCTI-111583	Journal Publication
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR®; SEVIKAR HCT®	Essential Hypertension	CS8635-A-E302	NCT00923091 2008-003534-25	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR®; SEVIKAR HCT®	Essential Hypertension	CS8635-A-E303	NCT00902538 2008-003535-20	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR®; SEVIKAR HCT®	Hypertension	CS8635-A-U301	NCT00649389	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine + Hydrochloro thiazide	TRIBENZOR®; SEVIKAR HCT®	Essential Hypertension	CS8635-SIT-11-01	NCT01838850
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J301	JapicCTI-060286	Summary Results (JapicCTI)
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J302	JapicCTI-060295	(JapicCTI)
Olmesartan Medoxomil + Azelnidipine	REZALTAS®	Hypertension	CS0866AZ-A-J303	JapicCTI-070449	Summary Results (JapicCTI)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT®; OLMETEC PLUS®	Type 2 Diabetes Mellitus	866-449	NCT00403481	Tabulated Results (CT.gov)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT®; OLMETEC PLUS®	Hypertension	CS866CM-B-E301	NCT00430508 2006-003876-37	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR HCT®; OLMETEC PLUS®	Essential Hypertension	CS866CM-B-E302	NCT00430950 2006-003877-28	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Olmesartan Medoxomil; Olmesartan Medoxomil + Hydrochloro thiazide	BENICAR®; OLMETEC®; BENICAR HCT®; OLMETEC PLUS®	Essential Hypertension	866-443	NCT00185068
Oxycodone	OXYCODONE	Healthy Subjects	DS5058-C-J106	JapicCTI-173793	Summary Results (JapicCTI)
Oxycodone	OXYCODONE	Healthy Subjects	DS5058-C-J104	JapicCTI-173606	Summary Results (JapicCTI)
Oxycodone	OXYCODONE	Healthy Subjects	DS5058-A-J101	JapicCTI-163475	Summary Results (JapicCTI)
Observational Study	N/A	Gastric Cancer	DS-ASCAHQ-ENH-GC001	NCT05606094
Observational Study	N/A	Hyper-cholesterolemia; Mixed Dyslipidemia	DSE-BMP-01-20	NCT04579367
Observational Study	N/A	Hypercholesterolemia; Mixed Dyslipidemia	SYROS-DSE-BMP-01-21-EU	NCT05546398
Observational Study	N/A	Dyslipidemic; Atherosclerotic Cardiovascular Disease; Hyper-cholesterolemia	DSE-HCL-01-19-EU	NCT04271280
Observational Study	N/A	Tenosynovial Giant Cell Tumors	DS-ONC-01-15-EU	NCT02948088	Tabulated Results (CT.gov)
Observational Study	N/A	Gastric Cancer; Gastroesophageal Junction Cancer; Colorectal Cancer	DS-Screen	JapicCTI-163380
Observational Study	N/A	Nonhemorrhagic Ischemic Stroke	ASBI 801	NCT01496885	Tabulated Results (CT.gov)
Observational Study	N/A	Healthy Subjects (Measure of Tidal Breathing)		JapicCTI-153093
Observational Study	N/A	Venous Thromboembolism	DSE-VTE-01-12	DRKS00004795

P

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	HERTHENA-Lung02 U31402-A-U301	NCT05338970 2021-005879-40 jRCT2021220002
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	U31402-A-U103	NCT04676477 jRCT2031200247
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	HERTHENA-Lung01 U31402-A-U201	NCT04619004 2020-000730-17 jRCT2031200186
Patritumab Deruxtecan (U3-1402)		Colorectal Cancer	U31402-A-U202	NCT04479436 2019-004418-32 jRCT2031200139
Patritumab Deruxtecan (U3-1402)		Non-small Cell Lung Cancer	U31402-A-U102	NCT03260491 2017-000543-41 JapicCTI-194868
Patritumab Deruxtecan (U3-1402)		Breast Cancer	U31402-A-J101	NCT02980341 JapicCTI-163401
Pexidartinib	TURALIO™️	Tenosynovial Giant Cell Tumor	PL3397-A-J304	NCT04703322 jRCT2041200074
Pexidartinib	TURALIO™️	Tenosynovial Giant Cell Tumor	PL3397-A-U401	NCT04635111
Pexidartinib	TURALIO™️	Tenosynovial Giant Cell Tumor	PL3397-A-A303	NCT04488822
Pexidartinib	TURALIO™️	Moderate Hepatic Impairment	PL3397-A-U129	NCT04223635	Tabulated Results (CT.gov)
Pexidartinib	TURALIO™️	Tenosynovial Giant Cell Tumor; KIT-mutant Tumor; Other Solid Cancer	PL3397-A-U126	NCT03291288	Tabulated Results (CT.gov)
Pexidartinib	TURALIO™️	Advanced Solid Cancer	PL3397-A-A103	NCT02734433	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Melanoma; Non-small Cell Lung Cancer; Head and Neck Cancer; Gastrointestinal Stromal Tumor (GIST); Ovarian Cancer	PLX108-14	NCT02452424	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Melanoma	PLX108-13	NCT02975700	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Pigmented Villonodular Synovitis; Giant Cell Tumor of the Tendon Sheath	PLX108-10	NCT02371369 2014-000148-14	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Melanoma	PLX108-09	NCT01826448	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Glioblastoma	PLX108-08	NCT01790503	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Solid Cancer	PLX108-07	NCT01525602	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Prostate Cancer	PLX108-06	NCT01499043	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Acute Myeloid Leukemia	PLX108-05	NCT01349049	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Glioblastoma	PLX108-04	NCT01349036	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Hodgkin Lymphoma	PLX108-03	NCT01217229	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Solid Cancer	PLX108-01	NCT01004861	Tabulated Results (CT.gov) Plain Language Summary (EN)
Pexidartinib	TURALIO™️	Healthy Subjects	PL3397-A-U128	NCT03901313	Tabulated Results (CT.gov)
Pexidartinib	TURALIO™️	Healthy Subjects	PL3397-A-U122	NCT03138759	Plain Language Summary (EN)
Prasugrel	EFFIENT®	Acute Coronary Syndrome	CS747S-B-A4003	NCT03672097	Tabulated Results (CT.gov)
Prasugrel	EFFIENT®	Thrombotic Stroke	CS0747S-A-J305	JapicCTI-184141	Summary Results (JapicCTI)
Prasugrel	EFFIENT®	Cerebrovascular Accident	CS0747S-A-J304	JapicCTI-121901	Summary Results (JapicCTI)
Prasugrel	EFFIENT®	Cerebrovascular Accident	CS0747S-A-J303	JapicCTI-111582	Summary Results (JapicCTI)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS0747S-B-J302	JapicCTI-111550	Journal Publication
Prasugrel	EFFIENT®	Acute Coronary Syndrome	CS0747S-B-J301	JapicCTI-101339	Journal Publication
Prasugrel	EFFIENT®	Stroke	CS0747S-A-J203	JapicCTI-101044	Summary Results (JapicCTI)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4003	NCT01587651 2011-004064-29	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4002	NCT01260584	Tabulated Results (CT.gov)
Prasugrel	EFFIENT®	Coronary Artery Disease	CS747S-B-U4001	NCT01014624	Tabulated Results (CT.gov)
Perflubutane	SONAZOID®	Prostate Cancer	DD723-B-J301	JapicCTI-101308	Summary Results (JapicCTI)
Perflubutane	SONAZOID®	Breast Cancer	DD723-B-J302	JapicCTI-101287	Journal Publication
Perflubutane	SONAZOID®	Prostate Cancer	DD723-B-J201	JapicCTI-090893	Summary Results (JapicCTI)
Perflubutane	SONAZOID®	Breast Cancer	DD723-B-J202	JapicCTI-090894	Journal Publication
Pravastatin	MEVALOTIN®	Dyslipidemia	MVT-OS-21-01	NCT05120895
Pravastatin	MEVALOTIN®	Dyslipidemia Associated With Type 2 Diabetes Mellitus	MVT-OS-15-01	NCT05107063
Pravastatin	MEVALOTIN®	Hyperlipidemia	APPROACH-J	JapicCTI-080534
Pactimibe Sulfate	Discontinued	Atherosclerosis; Heterozygous Familial Hyper-cholesterolemia	505-205	NCT00151788
Pactimibe Sulfate	Discontinued	Coronary Artery Disease	505-202	NCT00185042
Pactimibe Sulfate	Discontinued	Atherosclerosis	SE-505/14	NCT00185146
Patritumab	Discontinued	Head and Neck Cancer	U31287-A-U203	NCT02633800 2015-002222-40	Tabulated Results (EU-CTIS)
Patritumab	Discontinued	Lung Cancer	U31287-A-J107	JapicCTI-152841
Patritumab	Discontinued	Head and Neck Cancer	U31287-A-U106	NCT02350712 2014-002445-22
Patritumab	Discontinued	Lung Cancer; Non-small Cell Lung Cancer	U31287-A-U301	NCT02134015 2013-004371-12	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Patritumab	Discontinued	Solid Cancer	U31287-A-U105	NCT01957280
Patritumab	Discontinued	Metastatic Breast Cancer	U3-1287-A-U202	NCT01512199
Patritumab	Discontinued	Lung Cancer	U31287-A-U201	NCT01211483 2010-021082-74	Tabulated Results (CT.gov) (EU-CTIS)
Patritumab	Discontinued	Non-small Cell Lung Cancer	U31287-A-U201E	2013-000104-42	Tabulated Results (EU-CTIS)
Patritumab	Discontinued	Breast Cancer	U31287-A-J103	JapicCTI-121772
Patritumab	Discontinued	Lung Cancer	U31287-A-J102	JapicCTI-111506
Patritumab	Discontinued	Solid Cancer	U31287-A-J101	JapicCTI-101262
Piclozotan	Discontinued	Parkinson's Disease	ASBI-501	NCT00623363	Tabulated Results (CT.gov)
Piclozotan	Discontinued	Acute Ischemic Stroke	SPI-103	NCT00272909 2004-002437-39	Summary Results (EU-CTIS)

Q

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-U202	NCT03793478
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-A103	NCT03723681
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia; Leukemia	AC220-A-U302	NCT02668653 2015-004856-24 JapicCTI-173667	Tabulated Results (CT.gov) (EU-CTIS)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-J201	NCT02984995 JapicCTI-163441	Tabulated Results (CT.gov) Summary Results (JapicCTI) Plain Language Summary (EN) (JP)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-A-J102	NCT02834390 JapicCTI-163309	Tabulated Results (CT.gov) Summary Results (JapicCTI) Plain Language Summary (EN) (JP)
Quizartinib	VANFLYTA®	Relapsed or Refactory Acute Myeloid Leukemia	AC220-A-J101	NCT02675478 JapicCTI-163142	Summary Results (JapicCTI) Plain Language Summary (EN) (JP)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-007	NCT02039726 2013-004890-28	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-2004	NCT01565668 2011-005408-13	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-0011	NCT01468467	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	2689-CL-0005	NCT01390337	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Solid Cancer	AC220-004	NCT01049893	Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	AC220-002	NCT00989261 2009-013093-41	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Acute Myeloid Leukemia	CP0001	NCT00462761	Tabulated Results (CT.gov) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Moderate Hepatic Impairment	AC220-A-U105	NCT04473664	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-A-U107	NCT04796831	Tabulated Results (CT.gov) Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-A-U106	NCT04459598	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-A-U104	NCT04459585	Tabulated Results (CT.gov)
Quizartinib	VANFLYTA®	Healthy Subjects; Liver Disease	AC220-016		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-015		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-014		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-012		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-008		Plain Language Summary (EN)
Quizartinib	VANFLYTA®	Healthy Subjects	AC220-006		Plain Language Summary (EN)

R

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Renadirsen (DS-5141)		Duchenne Muscular Dystrophy	DS5141-A-J201	NCT04433234 JapicCTI-205321
Renadirsen (DS-5141)		Duchenne Muscular Dystrophy	DS5141-A-J101	NCT02667483 JapicCTI-153072
RS Virus Vaccine (VN-0200)		Prevention of Respiratory Syncytial Virus Infection	VN0200-091	NCT05547087 jRCT2071220051
RS Virus Vaccine (VN-0200)		Prevention of Respiratory Syncytial Virus Infection	VN0200-A-J101	NCT04914520 jRCT2031210069
Rifampicin	RIFADIN®	Healthy Subjects	RIFADI-A-J101	JapicCTI-173675
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-U302	NCT00571519	Tabulated Results (CT.gov)
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-203	NCT00143520
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-A-U301	NCT00484198 2006-005047-28	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-J204	NCT00575471 JapicCTI-070424
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS011-A-J205	NCT00575874
Rivoglitazone	Discontinued	Type 2 Diabetes Mellitus	CS0011-A-U302	2007-005263-97	Summary Results (EU-CTIS)

S

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Sitafloxacin	GRACE BIT®	COPD Exacerbation Acute	DSCN-GRV AECOPD-CSIS-001	NCT05400369
Sitafloxacin	GRACE BIT®	Infections	DU6859-A-J301	JapicCTI-090731	Summary Results (JapicCTI)
Sitafloxacin	GRACE BIT®	Infections	DU6859a-49	JapicCTI-050062
Sitafloxacin	GRACE BIT®	Infections	DU6859a-43	JapicCTI-050063
Sitafloxacin	GRACE BIT®	Infections	DU6859a-48	JapicCTI-050064
Sitafloxacin	GRACE BIT®	Infections	DU6859a-47	JapicCTI-050065
Sitafloxacin	GRACE BIT®	Infections	DU6859a-45	JapicCTI-050066
Sitafloxacin	GRACE BIT®	Infections	DU6859a-44	JapicCTI-050067
Sitafloxacin	GRACE BIT®	Infections	DU6859a-42	JapicCTI-050068
Sitafloxacin	GRACE BIT®	Infections	DU6859a-46	JapicCTI-050069
Soblidotin	Discontinued	Soft Tissue Sarcoma	CDR0000310138	NCT00064220
Soblidotin	Discontinued	Non-small Cell Lung Cancer	CDR0000301749	NCT00061854
SUN13834	Discontinued	Atopic Dermatitis	ASBI 404	NCT00717769
SUN13837	Discontinued	Acute Spinal Cord Injury	ASBI 603	NCT01502631 2012-004373-80	Tabulated Results (CT.gov) (EU-CTIS)
SUN13837	Discontinued	Stroke	ASBI 802	NCT02258880
Sodium Hyaluronate	N/A	Hip Osteoarthritis	ADA 2003-01	NCT00330135
Spironolactone	N/A	Diabetes	N/A	JapicCTI-132140

T

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol	Access to Study Results and Plain Language Summaries
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Non-small Cell Lung Cancer	ENH-DS-22004	jRCT2071220096
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung04 D967SC00001	jRCT2011210058
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast11 D967RC00001	jRCT2041210097
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast12 D9673C00007	jRCT2031210182
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Solid Cancer	DESTINY-PanTumor01 D967MC00001	jRCT2031210132
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast09 D967UC00001	jRCT2031210130
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Colorectal Cancer	DESTINY-CRC02 DS8201-A-U207	NCT04744831 2020-004782-39 jRCT2051200124
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DESTINY-Gastric04 DS8201-A-U306	NCT04704934 2020-004559-34 jRCT2031200369
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung02 DS8201-A-U206	NCT04644237 2020-003427-42 jRCT2061200038
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast05 DS8201-A-U305	NCT04622319 2020-003982-20 jRCT2061200033
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast06 D9670C00001	jRCT2061200028
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer	DESTINY-Gastric03 D967LC00001	jRCT2031200203
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer; Non-small Cell Lung Cancer	DS8201-A-U106	NCT04042701 2018-002489-38
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer	DESTINY-Gastric02 DS8201-A-U205	NCT04014075 2019-001512-34	Tabulated Results (CT.gov) (EU-CTIS)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast04 DS8201-A-U303	NCT03734029 2018-003069-33 JapicCTI-184223
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast03 DS8201-A-U302	NCT03529110 2018-000222-61 JapicCTI-183976	Tabulated Results (CT.gov) (EU-CTIS)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast02 DS8201-A-U301	NCT03523585 2018-000221-31 JapicCTI-184017
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer; Urothelial Cancer	DS8201-A-U105	NCT03523572 2018-000371-32	Tabulated Results (CT.gov)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Non-small Cell Lung Cancer	DESTINY-Lung01 DS8201-A-U204	NCT03505710 2017-004781-94 JapicCTI-183916	Tabulated Results (CT.gov) (EU-CTIS)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Colorectal Cancer	DESTINY-CRC01 DS8201-A-J203	NCT03384940 2017-003466-28 JapicCTI-173808	Tabulated Results (CT.gov) (EU-CTIS) Summary Results (JapicCTI)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Neoplasm Metastasis	DS8201-A-A104	NCT03383692 JapicCTI-173790	Tabulated Results (CT.gov)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer; Breast Cancer	DS8201-A-A103	NCT03368196	Tabulated Results (CT.gov) Plain Language Summary (EN)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DS8201-A-J102	NCT03366428 JapicCTI-173791	Tabulated Results (CT.gov) Summary Results (JapicCTI) Plain Language Summary (EN) (JP)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DS8201-C-J4001	JapicCTI-205234	Summary Results (JapicCTI)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	DESTINY-Gastric01 DS8201-A-J202	NCT03329690 JapicCTI-173727	Tabulated Results (CT.gov) Summary Results (JapicCTI)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Breast Cancer	DESTINY-Breast01 DS8201-A-U201	NCT03248492 2016-004986-18 JapicCTI-173693	Tabulated Results (CT.gov) (EU-CTIS) Plain Language Summary (EN) (JP)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	Advanced Solid Malignant Tumors	DS8201-A-J101	NCT02564900 JapicCTI-152978	Tabulated Results (CT.gov) Plain Language Summary (EN) (JP)
Trastuzumab Deruxtecan (DS-8201)	ENHERTU®	HER2-positive Breast Cancer	EUROPA T-DXd DS8201-0002-EAP-MA	NCT05458401
Tetravalent Combination Vaccine	SQUAREKIDS®	Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection	DD687-A-J301	JapicCTI-101350	Summary Results (JapicCTI)
Tetravalent Combination Vaccine	SQUAREKIDS®	Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection	DD687-A-J201	JapicCTI-090931	Summary Results (JapicCTI)
Tigatuzumab	Discontinued	Liver Cancer	CS1008-A-U204	NCT01033240 JapicCTI-101138
Tigatuzumab	Discontinued	Metastatic Colorectal Cancer	CS1008-A-U105	NCT01124630
Tigatuzumab	Discontinued	Ovarian Cancer	CS1008-A-U205	NCT00945191	Tabulated Results (CT.gov)
Tigatuzumab	Discontinued	Non-small Cell Lung Cancer	CS1008-A-E202	NCT00991796 2007-004574-11	Summary Results (EU-CTIS)
Tigatuzumab	Discontinued	Colorectal Cancer	CS1008-A-E203	NCT00969033 2007-005675-34	Summary Results (EU-CTIS)
Tigatuzumab	Discontinued	Pancreatic Cancer	CS1008-A-U201	NCT00521404	Tabulated Results (CT.gov)
Tigatuzumab	Discontinued	Solid Cancer; Lymphomas	CS1008-A-U101	NCT00320827
Tigatuzumab	Discontinued	Solid Cancer	CS1008-A-J104	JapicCTI-090892
Tivantinib	Discontinued	Inoperable Hepatocellular Carcinoma	ARQ197-A-U303	NCT01755767 2012-003308-10	Tabulated Results (CT.gov) (EU-CTIS)
Tivantinib	Discontinued	Non-squamous, Non-small Cell Lung Cancer	ARQ197-A-U302	NCT01244191 2010-022365-10
Tivantinib	Discontinued	Solid Cancer; Hepatic Impairment	ARQ197-A-U160	NCT02150733
Tivantinib	Discontinued	Colorectal Cancer	ARQ197-A-U252	NCT01075048 2009-016025-34	Tabulated Results (CT.gov) (EU-CTIS)
Tivantinib	Discontinued	Solid Cancer	ARQ197-A-U158	NCT01517399
Tivantinib	Discontinued	Cancer	ARQ197-A-U159	NCT01699061
Tivantinib	Discontinued	Non-CNS Germ Cell Tumors	ARQ197-A-U251	NCT01055067 2009-015400-26	Tabulated Results (CT.gov) Summary Results (EU-CTIS)
Tivantinib	Discontinued	Solid Cancer	ARQ197-A-U157	NCT01149720

U

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol
U3-1565	Discontinued	Advanced Solid Malignant Tumors; Advanced Ovarian Cancer	U31565-A-U101	NCT01290471
U3-1565	Discontinued	Solid Cancer	U31565-A-J102	JapicCTI-111484
U3-1784	Discontinued	Advanced Solid Cancer; Hepatocellular Cancer	U31784-A-E101	NCT02690350

V

Generic Name / Project Code	Trade Name	Medical Condition	Study Code	Access to Study Protocol
Valemetostat (DS-3201)	EZHARMIA®	Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/ Lymphoma	DS3201-A-U202	NCT04703192 jRCT2071200095
Valemetostat (DS-3201)	EZHARMIA®	Hepatic Impairment	DS3201-A-U106	NCT04276662
Valemetostat (DS-3201)	EZHARMIA®	Adult T-cell Leukemia/ Lymphoma	DS3201-A-J201	NCT04102150 JapicCTI-194964
Valemetostat (DS-3201)	EZHARMIA®	Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia	DS3201-A-U102	NCT03110354
Valemetostat (DS-3201)	EZHARMIA®	Non-hodgkin Lymphoma	DS3201-A-J101	NCT02732275 JapicCTI-163173
Valemetostat (DS-3201)	EZHARMIA®	Healthy Subjects	DS3201-A-J109	jRCT2071200043
Valemetostat (DS-3201)	EZHARMIA®	Healthy Subjects	DS3201-A-J107	JapicCTI-205338
Valemetostat (DS-3201)	EZHARMIA®	Healthy Subjects	DS3201-A-J104	JapicCTI-183902
Valemetostat (DS-3201)	EZHARMIA®	Healthy Subjects	DS3201-A-J103	JapicCTI-173804